FDA Brief

Warning letters Drugs

FDA warning letter to

Dextrum Laboratories Inc.

High riskIssued Dec 7, 2023Posted Dec 26, 2023Division of Pharmaceutical Quality Operations II

FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

What happened

FDA inspected Dextrum’s Miami drug manufacturing facility from July 10 to 18, 2023. FDA found the company did not perform at least one identity test for each component lot, did not adequately test each lot of high-risk components such as glycerin for diethylene glycol (DEG) or ethylene glycol (EG) contamination, and did not adequately monitor microbiological quality of water used in many OTC products. FDA also found process validation was inadequate for the OTC drugs it makes under contract and cited repeated similar CGMP (current good manufacturing practice) failures.

What FDA found

  1. Failed to perform at least one identity test for each component lot used in OTC drugs, including dextromethorphan active ingredient.

    21 CFR 211.84(d)(1)
  2. Failed to test each shipment of each lot of high-risk components such as glycerin for diethylene glycol (DEG) or ethylene glycol (EG) contamination with the USP identity test.

    21 CFR 211.84(d)(1)
  3. Failed to conduct microbiological testing before use of each lot of a component that could have objectionable microbiological contamination.

    21 CFR 211.84(d)(6)
  4. Failed to adequately monitor microbiological quality of water used as a component in many OTC products, testing it only on a (b)(4) basis.

    21 CFR 211.84(d)(6)
  5. Failed to adequately validate production and process controls; it validated one drug in each of three groups but did not show that this represented its other drug products.

    21 CFR 211.100(a)
  6. FDA cited repeated similar CGMP observations and inadequate quality systems and executive management oversight.

    21 CFR parts 210 and 211

What FDA wants

FDA tells Dextrum to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks for specific commitments, including DEG/EG test results within 30 calendar days for retained high-risk component lots or implicated finished batches, a risk assessment for products within expiry, and third-party review of validation activities.

Who should pay attention

  • brands that buy OTC cough/cold products from this contract manufacturer
  • companies sourcing glycerin or other high-risk drug components
  • retailers and distributors of Dextrum-made OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk